Company Filing History:
Years Active: 2025
Title: Innovations of Inventor Zhoufan Xie in RET Inhibitors
Introduction
Zhoufan Xie is a notable inventor based in Guangdong, China, recognized for his contributions to the field of medicinal chemistry. Holding two patents, his work focuses on developing innovative compounds that serve as RET kinase inhibitors, which are crucial for therapeutic applications in treating various diseases.
Latest Patents
Zhoufan Xie's latest patents illustrate his commitment to advancing medical science. The first patent details a series of pyrazolopyridine compounds and their application in the preparation of RET kinase inhibitors designed for treatment purposes. Specifically, it discloses a compound represented by a specific formula, as well as its pharmaceutically acceptable salts. His second patent introduces nitrogen-containing spiro derivatives that also function as RET inhibitors. This patent outlines a series of compounds with a unique spiro structure and their applications in the creation of RET kinase inhibitors, detailing a compound shown in another designated formula, along with its pharmaceutically acceptable salts.
Career Highlights
Zhoufan Xie is currently affiliated with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., specifically within the Baiyunshan Pharmaceutical General Factory. His role at this reputable company allows him to contribute significantly to pharmaceutical innovations and advancements in drug development.
Collaborations
Throughout his career, Zhoufan has collaborated with talented individuals in the field, including coworkers Jiansong Wang and Zhibo Luo. These collaborations have fostered an environment of innovation and have led to significant breakthroughs in the research and development of RET inhibitors.
Conclusion
With a focus on developing novel compounds for treating illnesses, Zhoufan Xie's work exemplifies the spirit of innovation in the pharmacological field. His patents not only demonstrate his inventive capabilities but also contribute to advancing therapeutic strategies against diseases related to RET kinase.